Galera Therapeutics (GRTX) sets 2026 meeting date and April 13 proposal deadline
Rhea-AI Filing Summary
Galera Therapeutics, Inc. has scheduled its Combined 2025 and 2026 Annual Meeting of Stockholders for May 8, 2026. Because this date is more than 60 days after the prior Annual Meeting held on February 24, 2025, the company is updating key stockholder proposal and nomination deadlines.
Stockholders seeking to nominate directors or present other business under the company’s Amended and Restated Bylaws must deliver notice to the secretary at the principal executive office by April 13, 2026. To use the universal proxy rules under Rule 14a-19, stockholders soliciting proxies for alternative nominees must also provide the required notice by April 13, 2026. The company will treat stockholder proposals received on or before April 13, 2026 as received a reasonable time before it prints and mails proxy materials for possible inclusion under Rule 14a-8.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Annual meeting date: May 8, 2026
Bylaw notice deadline: April 13, 2026
Universal proxy notice deadline: April 13, 2026
+2 more
5 metrics
Annual meeting date
May 8, 2026
Combined 2025 and 2026 Annual Meeting of Stockholders
Bylaw notice deadline
April 13, 2026
Deadline for director nominations and other business under bylaws
Universal proxy notice deadline
April 13, 2026
Rule 14a-19(b) notice for alternative director nominees
Proxy inclusion reference date
April 13, 2026
Proposals on or before this date deemed timely under Rule 14a-8
Prior annual meeting date
February 24, 2025
Anniversary date used to assess 60-day timing difference
Key Terms
Annual Meeting of Stockholders, Amended and Restated Bylaws, advance notice provisions, universal proxy rules, +2 more
6 terms
Annual Meeting of Stockholders financial
"The Combined 2025 and 2026 Annual Meeting of Stockholders (the “Annual Meeting”) of Galera Therapeutics, Inc."
Amended and Restated Bylaws regulatory
"must comply with the requirements set forth in the Company’s Amended and Restated Bylaws (the “Bylaws”)."
A company’s amended and restated bylaws are its internal rulebook rewritten to include all changes in one updated document, replacing the old bylaws. For investors, this matters because the bylaws set how the board, shareholders and officers make decisions, hold votes and handle disputes; a new consolidated version can change voting rights, control mechanisms or procedures that affect corporate governance and the value or risk of an investment.
advance notice provisions regulatory
"The advance notice provisions of the Bylaws contain informational content requirements"
Advance notice provisions are rules in a company’s bylaws that require shareholders or potential board candidates to give written notice — by a set deadline — before proposing agenda items or nominating directors for a shareholder meeting. Like an RSVP and agenda deadline for a meeting, they help the company plan and prevent last-minute surprises; for investors, they shape the timing and feasibility of shareholder campaigns and influence how quickly governance changes can occur.
universal proxy rules regulatory
"To comply with the universal proxy rules pursuant to Rule 14a-19 under the Exchange Act"
Universal proxy rules require that when shareholders vote to elect directors in a contested election, the proxy card mailed to investors can include candidates nominated by both the company and dissident shareholders, letting investors mix and match their choices on a single ballot. This matters to investors because it makes their vote more flexible and easier to use, like replacing separate lists with one common ballot, which can influence who controls the board and the company’s future direction.
Rule 14a-8 regulatory
"inclusion of a stockholder proposal in the Company’s proxy materials pursuant to Rule 14a-8 under the Securities Exchange Act of 1934"
Rule 14a-8 is a U.S. Securities and Exchange Commission regulation that lets eligible shareholders put proposals on a public company’s proxy ballot for an annual meeting, provided they meet basic ownership and filing requirements. It matters to investors because it creates a formal way to raise governance or strategic issues and force a company-wide vote—like getting an item onto the agenda of a neighborhood association meeting once you’ve lived there long enough—so shareholders can push for change or influence management decisions.
Rule 14a-19 regulatory
"pursuant to Rule 14a-19 under the Exchange Act, stockholders who intend to solicit proxies"
Rule 14a-19 is a U.S. Securities and Exchange Commission rule that governs how independent proxy advisory firms produce and distribute voting recommendations for shareholders. It requires these advisers to provide companies with notice of their recommendations and a chance to respond, and to disclose certain conflicts; think of it as a referee ensuring both sides see a game plan before fans cast votes. Investors care because proxy advisers influence voting outcomes and corporate governance, so the rule affects transparency, potential bias, and the reliability of guidance that many investors rely on when voting shares.
FAQ
When is Galera Therapeutics (GRTX) holding its Combined 2025 and 2026 Annual Meeting?
Galera Therapeutics plans to hold its Combined 2025 and 2026 Annual Meeting of Stockholders on May 8, 2026. This meeting date is more than 60 days after the prior Annual Meeting held on February 24, 2025, triggering revised stockholder proposal deadlines.
What is the deadline for Galera Therapeutics (GRTX) stockholders to submit director nominations or other proposals?
Stockholders must deliver director nominations or other proposals under the company’s bylaws by April 13, 2026. Notices must be delivered or mailed to the secretary at Galera’s principal executive office in Malvern, Pennsylvania, in accordance with the advance notice provisions of the bylaws.
How do universal proxy rules under Rule 14a-19 affect GRTX stockholder nominations?
Stockholders planning to solicit proxies for director nominees other than Galera’s nominees must provide a Rule 14a-19(b) notice by April 13, 2026. This notice, containing the required information, must be postmarked or electronically transmitted to the company’s principal executive office by that date.
What is the deadline to have a stockholder proposal included in GRTX’s proxy materials under Rule 14a-8?
For potential inclusion in Galera’s proxy materials under Rule 14a-8, proposals must reach the principal executive office a reasonable time before printing and mailing. The company will deem proposals received on or before April 13, 2026 to be timely for this purpose.
Where must Galera Therapeutics (GRTX) stockholder notices and proposals be sent?
All qualifying stockholder notices and proposals must be delivered to the secretary, Joel Sussman, at Galera Therapeutics’ principal executive office. The address is 101 Lindenwood Drive, Suite 225, Malvern, Pennsylvania 19355, which is the designated location for receiving such submissions.
Why did GRTX update its stockholder proposal deadlines for the 2025–2026 Annual Meeting?
Galera updated deadlines because the May 8, 2026 Annual Meeting is more than 60 days after the prior meeting on February 24, 2025. This timing difference requires the company to set new advance notice and proxy-related deadlines for stockholder nominations and proposals.
AI-generated analysis. How Rhea-AI works. Not financial advice.
